United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Invests $69.36 Million in Merck & Co., Inc. $MRK

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, Holdings Channel reports. The fund purchased 658,905 shares of the company’s stock, valued at approximately $69,356,000. Merck & Co., Inc. comprises about 1.0% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings, making the stock its 22nd largest position.

Other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in Merck & Co., Inc. by 36.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 416,488 shares of the company’s stock valued at $43,840,000 after acquiring an additional 112,341 shares during the period. Ilmarinen Mutual Pension Insurance Co increased its position in Merck & Co., Inc. by 2.0% in the 4th quarter. Ilmarinen Mutual Pension Insurance Co now owns 441,500 shares of the company’s stock valued at $46,472,000 after acquiring an additional 8,500 shares during the period. Moors & Cabot Inc. increased its position in Merck & Co., Inc. by 6.2% in the 4th quarter. Moors & Cabot Inc. now owns 97,972 shares of the company’s stock valued at $10,313,000 after acquiring an additional 5,726 shares during the period. EagleClaw Capital Managment LLC increased its position in Merck & Co., Inc. by 0.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 31,963 shares of the company’s stock valued at $3,364,000 after acquiring an additional 120 shares during the period. Finally, Investment Partners LTD. increased its position in Merck & Co., Inc. by 2.1% in the 4th quarter. Investment Partners LTD. now owns 5,021 shares of the company’s stock valued at $529,000 after acquiring an additional 103 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $119.87 on Friday. Merck & Co., Inc. has a twelve month low of $75.40 and a twelve month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $296.05 billion, a price-to-earnings ratio of 33.77, a PEG ratio of 2.71 and a beta of 0.18. The firm has a 50-day moving average of $116.31 and a two-hundred day moving average of $111.41.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the company earned $2.22 EPS. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Analysts Set New Price Targets

Several analysts recently commented on MRK shares. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. raised their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Guggenheim lifted their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call – Slideshow

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.